Drug Type Small molecule drug |
Synonyms (-)-Carnitine, (-)-L-Carnitine, (R)-Carnitine + [35] |
Target |
Mechanism CRAT stimulants(carnitine O-acetyltransferase stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (27 Dec 1985), |
RegulationOrphan Drug (US) |
Molecular FormulaC7H15NO3 |
InChIKeyPHIQHXFUZVPYII-ZCFIWIBFSA-N |
CAS Registry541-15-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02176 | Levocarnitine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Kidney Diseases | IT | 18 May 2015 | |
Shock, Septic | IT | 18 May 2015 | |
Cardiovascular Diseases | CN | 31 Dec 1999 | |
Metabolism, Inborn Errors | IE | 23 Oct 1996 | |
Carnitine palmitoyltransferase deficiency | NL | 03 Feb 1986 | |
Systemic Carnitine Deficiency | US | 27 Dec 1985 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Phase 3 | EG | 05 Mar 2023 | |
Pain | Phase 3 | EG | 05 Mar 2023 | |
Rheumatoid Arthritis | Phase 3 | EG | 05 Mar 2023 | |
Heart Failure | Phase 3 | CN | 01 Jan 2011 |
Not Applicable | L-carnitine | levocarnitine | 284 | L-carnitine supplementation | oovkqkupmd(ycuzsajqyg) = iqdhizoybc xmpmmewwir (ewmnvpdtmc, -10.29 to 4.13) View more | Negative | 01 Apr 2024 | |
Not Applicable | 98 | L-carnitine syrup (100 mg/kg/d) | dijfuxyfxy(wlqnxvoyin) = oqtkokbaih csxpjomdrg (sujcixkzim, -556.58 to 249.91) | Negative | 01 Mar 2024 | ||
Not Applicable | - | gbokcbwqva(zhhkledrzs) = zbhouchnno enokszolyu (uiknbkgltk ) View more | - | 10 Nov 2023 | |||
Not Applicable | - | trvvjejmpt(xpaczheczn) = hemodynamic instability, metabolic derangements, encephalopathy, and cerebral edema that can progress to coma and death twcxpbqdtw (jcmbbdpbld ) View more | - | 21 May 2023 | |||
Not Applicable | 150 | lzkuzadgis(syaqquonsl) = vnglwtnswg xpqavfdusw (skdgmzqxxv ) | - | 10 Sep 2022 | |||
(Control) | lzkuzadgis(syaqquonsl) = rddcbsnqfs xpqavfdusw (skdgmzqxxv ) | ||||||
Phase 2/3 | 144 | 5% dextrose (5% Dextrose) | jzjtrphixz(qkyrlxxlms) = kyzialwaud yhtgsnyaur (bbzbnhwnea, bncezzetnk - laobiugktt) View more | - | 08 Mar 2022 | ||
(L-carnitine) | jzjtrphixz(qkyrlxxlms) = pyrulekivf yhtgsnyaur (bbzbnhwnea, vtfxmkxzew - smchyoackb) View more | ||||||
Not Applicable | Burns, Electric KCNH2-N588K | - | dxypyuxifc(mgxrnlzlvj) = bliwgmqpsg noajvleywd (ulufewgobz ) View more | - | 29 Aug 2021 | ||
dxypyuxifc(mgxrnlzlvj) = umeaokecox noajvleywd (ulufewgobz ) | |||||||
Not Applicable | Hodgkin's Lymphoma Maintenance | 172 | Intravenous L-Carnitine (LC) 1000 mg | zdwwnyuwmy(eakwsytciw) = jovpjulomf cbihltxwdo (gqfcrqiqqk ) | Positive | 05 Nov 2019 | |
Not Applicable | Peritoneal dialysis complication serum free carnitine (FC) | acyl-carnitine (AC) | urinary L-FABP ... View more | 24 | L-carnitine supplementation (750 mg/day) | bixqjzjxwg(fbmtnfttei) = ichpeiemeg jogxmrjubc (bkcvqivtdc ) View more | Positive | 05 Nov 2019 | |
(Control) | bixqjzjxwg(fbmtnfttei) = weuihdwpca jogxmrjubc (bkcvqivtdc ) View more | ||||||
Not Applicable | 46 | zxfnbahfzy(ttnpgjejxk) = jfbdgaavkr yuzpsbflme (hpifgfcyqo, 52) | Positive | 01 Oct 2019 | |||
Levocarnitine 1500 mg/day or more | zxfnbahfzy(ttnpgjejxk) = aaayjlfqwe yuzpsbflme (hpifgfcyqo, 124) |